GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
GO:00302585 | Liver | NAFLD | lipid modification | 49/1882 | 212/18723 | 1.97e-08 | 2.17e-06 | 49 |
GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
GO:00060666 | Liver | NAFLD | alcohol metabolic process | 62/1882 | 353/18723 | 9.01e-06 | 2.96e-04 | 62 |
GO:00714663 | Liver | NAFLD | cellular response to xenobiotic stimulus | 33/1882 | 177/18723 | 3.54e-04 | 5.36e-03 | 33 |
GO:00335596 | Liver | NAFLD | unsaturated fatty acid metabolic process | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
GO:00016763 | Liver | NAFLD | long-chain fatty acid metabolic process | 23/1882 | 112/18723 | 6.73e-04 | 8.66e-03 | 23 |
GO:01202545 | Liver | NAFLD | olefinic compound metabolic process | 28/1882 | 153/18723 | 1.28e-03 | 1.45e-02 | 28 |
GO:00068054 | Liver | NAFLD | xenobiotic metabolic process | 22/1882 | 111/18723 | 1.42e-03 | 1.58e-02 | 22 |
GO:00066334 | Liver | NAFLD | fatty acid biosynthetic process | 29/1882 | 163/18723 | 1.67e-03 | 1.74e-02 | 29 |
GO:00424452 | Liver | NAFLD | hormone metabolic process | 36/1882 | 218/18723 | 1.98e-03 | 1.98e-02 | 36 |
GO:0070988 | Liver | NAFLD | demethylation | 16/1882 | 73/18723 | 2.09e-03 | 2.06e-02 | 16 |
GO:0008210 | Liver | NAFLD | estrogen metabolic process | 10/1882 | 38/18723 | 3.49e-03 | 3.00e-02 | 10 |
GO:00066906 | Liver | NAFLD | icosanoid metabolic process | 22/1882 | 123/18723 | 5.33e-03 | 4.11e-02 | 22 |
GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYP2C8 | SNV | Missense_Mutation | | c.1395N>T | p.Lys465Asn | p.K465N | P10632 | protein_coding | deleterious(0.04) | benign(0.101) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP2C8 | SNV | Missense_Mutation | novel | c.22G>A | p.Val8Met | p.V8M | P10632 | protein_coding | deleterious(0.05) | benign(0.059) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP2C8 | SNV | Missense_Mutation | | c.1240N>T | p.Asp414Tyr | p.D414Y | P10632 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP2C8 | SNV | Missense_Mutation | rs758378725 | c.314N>T | p.Arg105Ile | p.R105I | P10632 | protein_coding | deleterious(0.01) | benign(0.209) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP2C8 | SNV | Missense_Mutation | novel | c.239A>G | p.Tyr80Cys | p.Y80C | P10632 | protein_coding | deleterious(0.01) | probably_damaging(0.919) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CYP2C8 | SNV | Missense_Mutation | rs758378725 | c.314N>T | p.Arg105Ile | p.R105I | P10632 | protein_coding | deleterious(0.01) | benign(0.209) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CYP2C8 | SNV | Missense_Mutation | | c.599N>T | p.Arg200Ile | p.R200I | P10632 | protein_coding | tolerated(0.41) | benign(0) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
CYP2C8 | SNV | Missense_Mutation | rs543793530 | c.557G>A | p.Arg186Gln | p.R186Q | P10632 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP2C8 | insertion | Frame_Shift_Ins | novel | c.1264_1265insA | p.Ser422LysfsTer2 | p.S422Kfs*2 | P10632 | protein_coding | | | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP2C8 | SNV | Missense_Mutation | novel | c.1433C>G | p.Ser478Cys | p.S478C | P10632 | protein_coding | tolerated(0.08) | possibly_damaging(0.473) | TCGA-DD-AAD6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | rucaparib | RUCAPARIB | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | mycophenolate mofetil | | 24681964 |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | simeprevir | SIMEPREVIR | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | inhibitor | 404859006 | VOXELOTOR | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | repaglinide | REPAGLINIDE | 17923851,15961978,14534525,18388877,21270106 |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | inhibitor | 178103840 | PHENELZINE | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | fluvastatin | FLUVASTATIN | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | clopidogrel | CLOPIDOGREL | 24971633 |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | hmg coa reductase inhibitors | | |
1558 | CYP2C8 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | | pamidronate | PAMIDRONIC ACID | 18594024 |